Description

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity[1].-4°C (Powder, sealed storage, away from moisture and light)-Applications-Cancer-Kinase/protease-Formula-N/A-Citation–References-[1]Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61.|[2]Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. |[3]Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.-CASNumber-2136633-23-1-MolecularWeight-149000 (average)-Compound Purity-99.0-SMILES-[Disitamab vedotin]-Research_Area-Cancer-Solubility-H2O-Target-Antibody-Drug Conjugates (ADCs);EGFR-Isoform-ErbB2/HER2-Pathway-Antibody-drug Conjugate/ADC Related;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK-MCE Product type-ADC Related